Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 32 - Disappointing Results of Two Human Trials of Monoclonal Antibodies in Parkinson’s Disease

  • Daniel Gibbs, Emeritus of Oregon Health and Science University
  • Book:
    Dispatches from the Land of Alzheimer's
    Published online:
    19 January 2024
    Print publication:
    22 February 2024, pp 130-133

  • Summary

    Like Alzheimer’s disease, Parkinson’s disease is a progressive, neurodegenerative disorder that involves deposits of an abnormal protein in the brain. In Alzheimer’s disease, these abnormal proteins are extracellular beta-amyloid and intraneuronal, hyperphosphorylated tau. In Parkinson’s disease, the neuropathological findings are protein deposits of aggregated alpha-synuclein found primarily within neurons in a part of the brainstem called the substantia nigra but in other locations as well. These clumps of alpha-synuclein are called Lewy bodies.

    In the August 4, 2022 issue of the New England Journal of Medicine, we have reports of two phase 2 human trials of monoclonal antibodies directed at alpha-synuclein in subjects with early-stage Parkinson’s disease, prasinezumab and cinpanemab.